



Please join us for an educational event

VYVGART Hytrulo®
(efgartigimod alfa and hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL | 200 mg/mL and 2000 U/mL

PLEASE JOIN US FOR THE FOLLOWING PRESENTATION:

Dosing and Administration overview for VYVGART Hytrulo®

WHEN:

10/16/2025

6:30 PM

Eastern Time

WHERE:

The Oceanaire Seafood Room

801 Aliceanna Street, Baltimore, MD

To register for this program, please contact your argenx Field Clinical Educator:

Gina Meza Hults +1 (857)3436856 or gmezahults@argenx.com



Please RSVP at least 3 days in advance of the program.

You must register to attend. Please scan the QR code with your mobile phone to confirm your registration.

This educational presentation is sponsored by argenx. It is offered solely for educational purposes. No CME will be granted. Attendance at this event is limited to licensed healthcare professionals (HCPs). Family members or guests are not permitted to attend this presentation if they are not an HCP practicing in a relevant therapeutic area. HCPs with Minnesota or Vermont medical licenses will not be offered hospitality due to state restrictions. Please be aware of your limitations prior to attendance as additional restrictions may apply based on state of licensure and institutional affiliations. argenx will report and publicly disclose the costs associated with any meal and/or beverage provided to HCPs as required by law.

INDICATION

VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

SELECT IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

VYVGART HYTRULO is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products, to hyaluronidase, or to any of the excipients of VYVGART HYTRULO. Reactions have included anaphylaxis and hypotension leading to syncope.